Evaluating Efferon LPS Hemoadsorption with Hemofiltration for Treating Moderate to Severe Acute Pancreatitis in Adults Aged 18 to 75

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a blood purification method called multimodal hemoperfusion using the Efferon4 LPS device along with hemofiltration HF or hemodiafiltration HDF in patients with acute pancreatitis. This study aims to reduce the severity of organ dysfunction, measured by the SOFA score, in this serious condition that can lead to multiple organ failure and high mortality. The Efferon4 LPS device targets inflammatory substances involved in acute pancreatitis, which is characterized by a complex inflammatory response. Participants will be randomly assigned to one of two groups one receiving standard care with HF or HDF alone, and the other receiving the same baseline therapy combined with the Efferon4 LPS hemoadsorption treatment. The therapy will begin within 24 hours of ICU admission and within 8 hours after enrollment. The choice between HF and HDF will be made by the treating physician based on individual patient needs. During the study, participants will be closely monitored with assessments including SOFA scores over 1 to 7 days, vasopressor-free days, oxygenation index, cardiac index, ICU stay length, mechanical ventilation duration, and renal replacement therapy duration. These measures will help evaluate the treatments impact on organ function and patient recovery. The overall study period includes follow-up monitoring up to 60 days. The study does not include healthy volunteers and targets adults aged 18 to 75 with moderate to severe acute pancreatitis.

Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis